Hinova Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Hinova Pharmaceuticals's earnings have been declining at an average annual rate of -2.5%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 100% per year.
Key information
-2.5%
Earnings growth rate
29.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -100.0% |
| Return on equity | -20.1% |
| Net Margin | n/a |
| Next Earnings Update | 24 Aug 2024 |
Revenue & Expenses Breakdown
How Hinova Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -266 | 82 | 227 |
| 31 Dec 23 | 0 | -294 | 88 | 248 |
| 30 Sep 23 | 2 | -317 | 91 | 271 |
| 30 Jun 23 | 2 | -319 | 93 | 278 |
| 31 Mar 23 | 2 | -290 | 93 | 245 |
| 31 Dec 22 | 2 | -302 | 97 | 251 |
| 30 Sep 22 | 0 | -319 | 98 | 264 |
| 30 Jun 22 | 0 | -306 | 90 | 259 |
| 31 Mar 22 | 0 | -343 | 88 | 290 |
| 31 Dec 21 | 0 | -306 | 80 | 265 |
| 31 Dec 20 | 0 | -490 | 62 | 429 |
| 31 Dec 19 | 4 | -112 | 13 | 116 |
| 31 Dec 18 | 4 | -39 | 7 | 49 |
Quality Earnings: 688302 is currently unprofitable.
Growing Profit Margin: 688302 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688302 is unprofitable, and losses have increased over the past 5 years at a rate of 2.5% per year.
Accelerating Growth: Unable to compare 688302's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688302 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).
Return on Equity
High ROE: 688302 has a negative Return on Equity (-20.06%), as it is currently unprofitable.